

LAW OFFICES
HYMAN, PHELPS & MCNAMARA, P.C.


5603.013.01

JOHN A. GILBERT, JR.

700 THIRTEENTH STREET, N.W.
SUITE 1200
WASHINGTON, D. C. 20005-5929
12021 737-5600
FACSIMILE
12021 737-9329
www.hpm.com

Direct Dial (202) 737-4293

June 12, 2007


Mia Brent

BY MESSENGER

Linden Barber, Esq.
Chief, Regulatory Section
Office of Chief Counsel
Drug Enforcement Administration
600 Army/Navy Drive
Arlington, Virginia 22202

Dear Mr. Barber:

I have attached some important information on the progress of McKesson's implementation of the Lifestyle Drug Monitoring Program. As I stated in our last conversation, McKesson has implemented this program "nationally" across its 30 distribution centers ("DC") throughout the country.

I have attached a copy of the following information:

- Amendment to the McKesson DC Operations Manual describing the standard operation procedures (SOPs) for the Lifestyle Drug Monitoring Program;
- PowerPoint presentation by Donald Walker, Senior Vice President of Distribution Operations, at McKesson's National Operations Conference in April 2007 (this included the entire distribution network leadership, managers and staff, 110 persons);
- Copy of letter being sent to Retail National Accounts (chain customers);
- Pharmacy questionnaire and declaration being used by McKesson sales staff for due diligence with retail accounts; and
- Excerpt from Daily Dosage Summary which identifies customers that have exceeded threshold for the current month; (DC 8,195 = Lakeland).

McKesson has already conducted a level 1 inquiry of all customers (other than VA hospitals and chain pharmacies) about their distribution practices. These contacts have been documented at each DC. The initial run of the daily dosage report identified more

2603 MAIN STREET
SUITE 760
IRVINE, CALIFORNIA 92614
(949) 553-7400
FAX: (949) 553-7433

4819 EMERSON BOULEVARD
SUITE 400
DURHAM, NORTH CAROLINA 27703
(919) 313-4750
FAX: (919) 313-4751

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000001

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001323
MCKMDL00355527

DEF-WV-01527.00001

DEF-WV-01527

Linten Barber, Esq.
June 12, 2007
Page 2


HYMAN, PHELPS & MCNAMARA, P.C.

than 4,400 entries across the 30 DCs where the threshold has been exceeded. McKesson is in the process of conducting a level 2 inquiry with those customers who have placed orders above the expected norm based on the customer's profile and threshold amounts. McKesson has already terminated or reduced some customers based on its preliminary analysis. The results of this due diligence will be documented at each DC.

I also want to note two anecdotal examples that McKesson provided to me that demonstrate the progress of the program within the first 45 days. First, McKesson found one case where its inquiry of a pharmacy customer alerted that customer to an employee theft. The customer reported this information to the local DEA office. Second, I have attached an e-mail from the McKesson Washington Court, Ohio DC Manager describing a contact he made to Kathy Chaney, Group Supervisor of the Columbus DEA office. McKesson is encouraging the DC managers to incorporate these contacts in implementation of the Lifestyle Drug Monitoring Program.

I trust you will find that this information provides further evidence of McKesson's commitment to improving its distribution monitoring systems. Please let me know if you have any questions.

Sincerely,



John A. Gilbert, Jr.
Counsel to McKesson Corporation

Attachments

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000002

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001324
MCKMDL00355528

DEF-WV-01527.00002

McKesson Operations Manual

for Pharma Distribution

MOM Main Index

Lifestyle Drug Monitoring Program

General Description	Author / Owner	Overview of Detailed Steps	Detailed Steps
Attachments	Revision History	Search DistOps	Contact Us

General Description

Task: This procedure outlines requirements and activities to proactively review customer's purchases of DEA identified "Lifestyle Drugs" and actions to take based upon analysis of customer purchases.

Purpose: McKesson has been proactively working with the DEA to enhance current practices for the monitoring and review of suspicious orders. Trends in the marketplace require McKesson to reevaluate the methodology utilized to review customer orders and their business models.

The DEA expects the supplier to "know their customer". This means understanding the customer's business, why they purchase as well as how much they purchase. Factors such as type of business, internet activities, type and quantity of products purchased should be considered when evaluating a customer.

Reports

Two Business Objects reports, Daily Dosage Summary Report and Dosage Limit Tracking Detail, have been developed to allow McKesson to monitor customer purchases of controlled substances by the net number of dosage units sold based on the DEA's Controlled Substance Generic Base Code ID. McKesson will investigate customer activity when sales of a given generic base ingredient exceed a predefined dosage unit threshold within a calendar month. Initially all items will be investigated at the same threshold level, however the level may be changed per item at Regulatory Affairs discretion. The same dosage threshold will be used for all classes of customers.

This reporting process is targeting controlled substances that the DEA considers "lifestyle" drugs. These drugs are highly abused and are commonly found in illegal internet pharmacies.

Currently, the controlled substances being monitored by these reports are:

Generic Ingredient	Base code	Dosage Threshold
Oxycodone	9143	8,000
Hydrocodone	9193	8,000
Alprazolam	2882	8,000
Phentermine	1640	8,000

Additions or deletions of items will be managed through the Regulatory Department by submitting a problem request to Business Intelligence- Functional (BI-FUNC).

For the purpose of these reports, all sales to a DEA license number are being accumulated, therefore sales to multiple account numbers with the same DEA license number are consolidated. Sales are added together regardless of fill dc.

Daily Dosage Summary Report

This report will summarize customers who have purchased quantities of all products containing the identified base code in excess of the threshold for the item. For example all sales and credits of McKesson items containing Hydrocodone will be added together and reported if the total doses exceeded 8,000 unit. The daily report will systemically be sent via email to the DCM and their designee, Sales Management, and Regulatory department. It will be the DCM's responsibility to review and act on the reports according to the processes listed below.

Review of Summary Report

The report will be generated as customers exceed the dosage unit threshold. Each customer appearing on the report must be evaluated to the legitimacy of their order quantity. Once an account appears on the report, it will continue to show up on the report until the end of the month. You should start your evaluation when the account appears on the report; do not wait until the end of the month to start the process.

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000003

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001325
MCKMDL00355529

DEF-WV-01527.00003

Lifestyle Drug Monitoring Program

Page 2 of 7

If the account is a large customer that McKesson expects to purchase in large quantities, for example: Institutional, warehouse accounts, government, or mail order, then you will generally only have to perform a Level I review. However, large spikes of any customer including hospitals, warehouse accounts, or government accounts must be evaluated.

Generic Dosage Limit Tracking Detail Report

This is an on demand report that allows a DC to research a customer that has been reported on the Summary Report. Once a customer has been identified from the summary report, this report will provide detail of all sales and credits during any given time frame.

The user logs into Business Objects, runs the report and enters the DEA numbers and dates of interest.

Manually Running Reports

Both reports can be run manually within Business Objects, they are located in the Corporate Documents folder.

Since the reports may run a long time, the user should run these reports using the Business Objects PC client rather than through the Business Objects web interface. Using the web interface, the reports may time out before completion.

Download and install the "Business Objects Full Client Reporter" following the instructions found on the Business Objects home page at [Business Objects](#).

Access to Business Objects is granted by making a standard request to IT Security. Complete an OnLine Access Request at [On Line Security Request Form](#).

Problems with installing or using Business Objects should be addressed by calling the McKesson Internal Help Desk at 888-HELPMCK.



Top

Author / Owner

Author: Keith McIntyre

Document Owner: Gary Hilliard



Top

Overview of Detailed Steps

1. *Level I Review*
2. *Level II Review*
3. *Level III Review*
4. *Actions if sales are not approved*
5. *LDMP Approval & Sign Off Process*
6. *Record Retention Methodology*



Top

Detailed Steps

1. *Level I Review*

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000004

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001326
MCKMDL00355530

DEF-WV-01527.00004

1.1 If the customer appears on a previous month's report for the same item

Evaluate the customer's purchases relative to the past three month's purchases. The evaluation should include but not necessarily be limited to the following criteria:

- ♦ Previous sales were validated and approved.
- ♦ Sales have not increased more than 25% from any previous month.
- ♦ Sales are not increasing steadily.
- ♦ Sales are consistent with the customer type.
- ♦ Sales are consistent with any previous Sales or Customer communication.

Document findings on the LDMP Tracking Spreadsheet.

1.2 Determine if the sales are approved or inconclusive

If the evaluation indicates that the customer's purchases are reasonable and that no further investigation is required, proceed to the LDMP Approval and Sign Off Step. If the evaluation is inconclusive continue to the next step to gather and analyze further information.

1.3 If this is the first time the item has been listed for the customer or further investigation is indicated

Proceed with the following evaluation steps until sales are determined to be reasonable for the customer.

- ♦ Generate and review the Dosage Limit Detail Report for the customer for the previous 6 months. Use this to review the last 6 months sales for any trends.
- ♦ Review daily DU45 Suspicious Orders Report for entries for this customer. Has the customer appeared previously? Have we reported their sales to the DEA via the DU45?
- ♦ Review Customer Purchasing Profile if one has been completed; are sales consistent with their profile?
- ♦ Perform a web search on the customer to review possible business practices
- ♦ Contact the appropriate Sales representative to determine reasoning behind the sales.
- ♦ Contact the customer to inquire on sales volume, expected volume and nature of business.

Document findings on the LDMP Tracking Spreadsheet.

1.4 Determine if the sales are approved or inconclusive

If the evaluation indicates that the customer's purchases are reasonable and that no further investigation is required, proceed to the LDMP Approval and Sign Off Step.

If the evaluation is not conclusive:

- ♦ Begin cutting order quantities on identified items
- ♦ Escalate to the Level II Review

 **Section Top**

2. Level II Review**2.1 Notify management that a Level II Review has been initiated**

Email the VPDO and the Director or VP of Regulatory Affairs to notify them that a Level II Review has been started.

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000005

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001327
MCKMDL00355531

DEF-WV-01527.00005

2.2 Conduct a customer site examination

Visit the customer's site with the intent to observe their location and clientele. Observations should include items such as the following:

- ♦ Customer Traffic - does the customer volume seem in line with their business type?
- ♦ Signage - does the customer advertise themselves to the public in a manner consistent with their business type?
- ♦ Location - is the customer's business in a site that appears consistent with their business type and volume? For example, consider the area's population and surrounding businesses.
- ♦ Store Size - does the customer's square footage appear to be appropriate for their business type and volume?

Document findings on the LDMP Tracking Spreadsheet.

2.3 Conduct an interview with the customer

If evidence is not conclusive at this point, the customer must be contacted and an interview conducted with them regarding their purchases. This meeting should be conducted with representation from both Sales and Operations.

At the conclusion of the interview, the customer signs the Customer Declaration of Controlled Substance Purchases attesting to their business practices. After the interview, the McKesson representative will complete and sign off on the LDMP Questionnaire; this questionnaire will summarize the customer's responses.

Important: The customer is not allowed to complete the questionnaire themselves, the questionnaire is meant to document interactive communications between McKesson and the customer.

Instructions for performing the interview

1. Notify the appropriate Sales team member that an interview must be conducted with the customer.
2. Sales or Operations should contact the customer and request a meeting at a mutually agreed upon date and time.
 - ♦ Schedule the meeting for as soon as is possible for all parties; the DEA expects McKesson's responses to suspicious activities to be prompt and timely.
 - ♦ Ensure that the customer understands that McKesson is performing due diligence activities for the benefit of both McKesson and the customer.
3. Print and review the LDMP Questionnaire and Customer Declaration of Controlled Substance Purchases prior to visiting the customer.
4. Conduct the interview.
5. Have the customer sign the declaration.
6. Thank the customer and exit the interview.
7. Complete and sign the LDMP Questionnaire based upon responses provided by the customer.

Document findings on the LDMP Tracking Spreadsheet.

2.4 Determine if the sales are approved or inconclusive

If the evaluation indicates that the customer's purchases are reasonable and that no further investigation is required, proceed to the LDMP Approval and Sign Off Step.

If the evaluation is not conclusive, escalate to the Level III Review.



Section Top

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000006

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001328
MCKMDL00355532

DEF-WV-01527.00006

3. Level III Review**3.1 Contact Home Office**

If Level I and Level II reviews have not been conclusive, Distribution and Sales should contact the Director or Vice President of Regulatory Affairs to discuss finding and determine next steps. The Regional SVP should be notified at this time regarding the escalation of review.

3.2 Contact the local DEA office

The local DEA office should be contacted to determine if the account is in good standing with the agency; this will be done by DC Management or Regulatory Affairs. Findings must be shared between DC Management and Regulatory Affairs.

3.3 Senior Management Review of Findings

Regulatory Affairs will schedule and conduct meetings with the Law Department and Senior Management to present the findings of the review process and discuss next steps.

3.4 Contact DEA Headquarters

With the Law Department's guidance, Regulatory Affairs or Counsel will contact the DEA Headquarters to discuss our findings.

3.5 Final determination if the sales are approved or inconclusive

The final review of customer purchases and decisions regarding their purchases will be determined by the Law Department and Senior Vice President.

**4. Actions if sales are not approved****4.1 DEA Notification**

Regulatory Affairs will notify the DEA Headquarters and Local Office of McKesson's findings and any decisions regarding continued business with the customer.

4.2 Customer Notification

If there are outcomes to the review that impact the customer relationship with McKesson, Sales or Distribution Management will notify the customer.

**5. LDMP Approval & Sign Off Process**

When a review of a customer's purchases is conducted, the attached form will be utilized to document findings and McKesson Management sign off.

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000007

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001329
MCKMDL00355533

DEF-WV-01527.00007

Lifestyle Drug Monitoring Program

Page 6 of 7

Required Sign Offs:

Level I Review:
DC Manager

Level II Review:
DC Manager, Sales Manager, Vice President of Operations (VPDO), Director or Vice President of Regulatory Affairs

Level III Review:
DC Manager, Sales Manager, Vice President of Operations (VPDO), Regional SVP, Director or Vice President of Regulatory Affairs, SVP of Operations

6. Record Retention Methodology

Records will be maintained centrally by Regulatory Affairs although it is recommended that the DC maintain a copy for their own records as well. Reports will be emailed to Regulatory Affairs monthly or on an "as completed" basis depending on the document.

Daily Dosage Tracking Reporting:
The distribution centers and Regulatory Affairs will maintain copies of the report generated on the last business day of the month for at least two years. The DC does not need to send a copy to Regulatory Affairs, they receive their own copy automatically.

LDMP Tracking Spreadsheet:
This report should be completed and sent to Regulatory Affairs by the 10th of the month for the previous month's data. Copies should be maintained for at least two years.

Email the report to Jan Phillips at jan.phillips@mckesson.com - In the subject include the following: "LDMP Tracking Report for DC xxx for month year".

Example: LDMP Tracking Report for DC 109 for May 2007

Investigation Documentation:
As each investigation is completed all the related documents should be attached into a single email to send to Regulatory Affairs. The number and type of supporting documents will depend on how in depth a review was necessary. The Daily Dosage Summary Report is not needed in the review's documentation because the DC and Regulatory Affairs will be maintaining the last report for the month.

Email the documentation to Jan Phillips at jan.phillips@mckesson.com - In the subject include the following text "customer DEA# YYYYMM Level x Review"

Example: PM0022929 200705 Level II Review



Top

Attachments

LDMP Tracking Log

Click to Open or Save

LDMP Customer Questionnaire

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000008

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001330
MCKMDL00355534


DEF-WV-01527.00008

Lifestyle Drug Monitoring Program

Page 7 of 7

 [Click to Open or Save](#)

LDMP Review McKesson Sign Off

 [Click to Open or Save](#)

LDMP Customer Declaration of Controlled Substance Purchases

 [Click to Open or Save](#)

 [Top](#)

Revision History

Revision #:

1.0

05/04/2007

Document Created

Revision #:

1.1

05/09/2007

Added oxycodone to questionnaire in question #8

Revision #:

1.2

05/15/2007

added Customer Declaration of Controlled Purchases

Revision #:

1.3

05/16/2007

corrected sign off sheet level III heading

Revision #:

1.4

05/16/2007

Removed "Draft" reference from the Declaration attachment

 [Top](#)

No email? Send your comments to: [MOM Feedback](#)

For Internal Use Only

Copyright © 2003-2004 McKesson Corporation. All Rights Reserved.

This page created 05/29/2007 using Zavanta® version 3.5

http://mcknethost.mckesson.com/distops/Manuals/MOM/zav_MOM-CTRL-004.asp

6/7/2007

Confidential / Exempt from FOIA. Subject to FRE 408.


MCK_WVA_000009

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001331
MCKMDL00355535

DEF-WV-01527.00009

Confidential / Exempt from FOIA. Subject to FRE 408.



Donald Walker
Senior Vice President
Distribution Operations

MCK_WVA_000010

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001332
MCKMDL00355536

DEF-WV-01527.00010



Discussion Topics

- ▶ Public Health Issue
- ▶ DEA Focus
- ▶ McKesson Involvement
- ▶ Current Status
- ▶ Lifestyle Drug Monitoring Program





Public Health Issues

- ▶ Abuse of prescription drugs has risen 66% since 2000
- ▶ Hot capital hill topic
- ▶ Opioid painkillers kill more than cocaine and heroin combined
- ▶ Rogue Internet pharmacies distributing
 - Oxycodone C-II opioid analgesic painkiller
 - Hydrocodone C-II and C-III opioid painkiller
 - Phentermine C-IV appetite suppressant
 - Alprazolam C-IV antidepressant



3

NATIONAL OPERATIONS CONFERENCE 2007

MCK_WVA_000012



DEA Focus

▶ Internet Pharmacies

- Investigative work hours have doubled
- Cutting supply critical to success
- 218 investigations in 2006

▶ Wholesalers

- DEA expects
 - We "know our customers"
 - Wholesalers accountable for controlling quantities shipped
 - 5000 dose units is "average"





McKesson Involvement

- ▶ Sept 05- DEA meeting in Wash DC
 - Outlined Internet issue
- ▶ Nov 05 – DEA notified McKesson
 - 6 pharmacies in Florida excessive Hydrocodone
- ▶ Jan 06 – Meeting with DEA in Wash DC
 - Clear message from DEA
- ▶ Oct 06 – Order to Show Cause
 - Response: Create MOU





Current Status

- ▶ Apr 07 – Meeting with DEA attorneys
 - Identified new customers and DC's
- ▶ What we have done
 - Created new report and process
 - Lifestyle Drug Monitoring Program
 - Drafted response to DEA
 - Added analyst to Regulatory group



Lifestyle Drug Monitoring Program (LDMP)

McKESSON
Empowering Healthcare

STARTS MAY 1st

- ▶ Focus on four drugs
- ▶ Measure by "dose units" rather than sell units
- ▶ Establish threshold for excessive quantities – 8000 dose units
- ▶ Thorough due diligence of customers exceeding threshold
- ▶ Reducing orders to customers
- ▶ Documentation and reporting to DEA




7

NATIONAL OPERATIONS CONFERENCE 2007

Lifestyle Drug Monitoring Program (LDMP)

McKESSON
Empowering Healthcare





Daily Dosage Summary Report

- ▶ Captures data on the 4 Lifestyle drugs
 - Oxycodone, Hydrocodone, Phentermine, Alprazolam
- ▶ Generic base code
- ▶ 8000 dose unit threshold
- ▶ Report will be emailed daily to DCM and designees



MCKESSON
Empowering Healthcare

DEA Dosage Summary

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
AA0551920	395036	8113	PM0003094	6,000	ANTHONY BROWN PH-PSSNY	HYDROCODONE	34	34	13,832
BB4874221	218326	8113	PM0003094	6,000	BAILEY PRESCRIP CRT EDI	HYDROCODONE	72	72	27,032
AB493010E	375170	8113	PM0003094	6,000	BARTLES PHCY EDI PSSNY	HYDROCODONE	36	36	9,516
BB1047100	139097	8113	PM0003094	6,000	BAYSIDE PHARMACY	HYDROCODONE	46	46	15,696
AB789069E	059485	8113	PM0003094	6,000	BROWNS PHCY PSSNY	HYDROCODONE	43	43	8,216
AB1706564	279206	8113	PM0003094	6,000	BURHENNS PHCY	HYDROCODONE	38	38	12,032
BF2057735	144246	8113	PM0003094	6,000	CUBA PHARMACY HEALTHMART	HYDROCODONE	37	37	13,448
BJ8183896	260662	8113	PM0003094	6,000	FILLMORE PHARMACY JARE	HYDROCODONE	57	57	21,216
BF2638569	140897	8113	PM0003094	6,000	FRONTIER PHARMACY	HYDROCODONE	80	80	26,424
BF2628569	140897	8113	PM0003094	6,000	FRONTIER PHARMACY	OXYCODONE	206	204	16,269
AG5338517	315994	8113	PM0003094	6,000	GEROULDS-HOFF-PSSNY-C	HYDROCODONE	34	34	10,032
BG0830340	810655	8113	PM0003094	6,000	GEROULDS-HORSE-PSSNY-C	HYDROCODONE	35	35	9,816
BG0830340	810655	8113	PM0003094	6,000	GEROULDS-HORSE-PSSNY-C	OXYCODONE	113	88	10,080
AG0553417	316133	8113	PM0003094	6,000	GEROULDS-MAIN-PSSNY-C	HYDROCODONE	40	40	15,180
AG0553417	316133	8113	PM0003094	6,000	GEROULDS-MAIN-PSSNY-C	OXYCODONE	80	78	11,020
BG9113072	855963	8113	PM0003094	6,000	GRANT STREET PHCY	HYDROCODONE	151	151	15,100
BH4613398	074476	8113	PM0003094	6,000	HENDERSON DRUG #1	HYDROCODONE	50	50	8,032
BH8151083	297755	8113	PM0003094	6,000	HENDERSON DRUG #3-EDI	HYDROCODONE	49	49	11,616
AB1115404	859877	8113	PM0003094	6,000	KINNEY DRUGS 09	OXYCODONE	84	76	12,400
AP111346E	850146	8113	PM0003094	6,000	KINNEY DRUGS 17	OXYCODONE	66	64	10,020
BK4725733	478874	8113	PM0003094	6,000	KINNEY DRUGS 31	OXYCODONE	119	119	11,620
BK955706E	779701	8113	PM0003094	6,000	KINNEY DRUGS 60	OXYCODONE	145	145	13,508
BK9555650	504855	8113	PM0003094	6,000	KINNEY DRUGS 60	OXYCODONE	98	92	8,522
BJE145153	147669	8113	PM0003094	6,000	LOCKPORT APOTHECARY EDI	HYDROCODONE	84	84	9,600
BM3004703	723246	8113	PM0003094	6,000	MEDICAL PARK PHARMACY	HYDROCODONE	141	141	21,616
BM3004703	723246	8113	PM0003094	6,000	MEDICAL PARK PHARMACY	OXYCODONE	178	177	16,500
FN0088668	844066	8113	PM0003094	6,000	NCS HTHCR/OMNI ROCHESTER	OXYCODONE	102	96	9,600
BN5345574	083303	8113	PM0003094	6,000	NIAGARA APOTHECARY	HYDROCODONE	124	124	13,116
BN4677615	043803	8113	PM0003094	6,000	NIAGARA PHARMACY	HYDROCODONE	151	151	21,016
BB575646E	195066	8113	PM0003094	6,000	OMNICARE OF WESTERN NY	ALPRAZOLAM	9	9	9,000
BO584134E	596581	8113	PM0003094	6,000	OUR LADY OF LOURDES QIP	OXYCODONE	100	98	8,800



10

NATIONAL OPERATIONS CONFERENCE 2007



Lifestyle Drug Monitoring Program (LDMP)

- ▶ Roll out plan
 - Using April data begin diligence
 - VA and RNA Accounts will be managed centrally
- ▶ Webinar May 9th
 - Include ARCOS clerks and other critical staff
- ▶ Sales training TBD



McKesson Corporation
One Post Street
San Francisco, CA 94104

McKESSON
Empowering Healthcare

June 1, 2007

Name
Title
Company
Address
City, ST, Zip

Dear Name,

I want to let you know about a change in McKesson's processes to better monitor and support the DEA's ongoing effort to control illegal internet pharmacies.

In an effort to combat inappropriate drug diversion through illegal internet pharmacies, McKesson has modified our monitoring processes on the distribution of certain controlled substance lifestyle drugs. Pharmaceutical wholesalers, including McKesson, are being held accountable for controlling the quantities of these drugs shipped to customers and will be held responsible for reviewing trends as indicated by customers' order history.

To better control the distribution of these drugs, McKesson has developed the Lifestyle Drug Monitoring Program (LDMP). This program began on May 1, 2007 and focuses on four drugs: Oxycodone, Hydrocodone, Phentermine and Alprazolam. Shipment and monitoring of these drugs will be measured by "dose units" rather than "sell units" with 8,000 dose units as the threshold for excessive quantities. The LDMP will also monitor customers exceeding the threshold, reduce orders if necessary and provide documentation and reporting to the DEA.

To help us better comply with DEA, please complete the following form and return it to me by Date. If you have any questions, please don't hesitate to contact me at XXX-XXX-XXXX.

Thank you,

VPSS
Vice President Strategic Solutions
McKesson Corporation


Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000021

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001343
MCKMDL00355547

DEF-WV-01527.00021



McKesson Corporation
One Post Street
San Francisco, CA 94104

McKESSON
Empowering Healthcare

June 1, 2007

Name
Title
Company
Address
City, ST, Zip

Dear Name,

I want to let you know about a change in McKesson's processes to better monitor and support the DEA's ongoing effort to control illegal internet pharmacies.

In an effort to combat inappropriate drug diversion through illegal internet pharmacies, McKesson has modified our monitoring processes on the distribution of certain controlled substance lifestyle drugs. Pharmaceutical wholesalers, including McKesson, are being held accountable for controlling the quantities of these drugs shipped to customers and will be held responsible for reviewing trends as indicated by customers' order history.

To better control the distribution of these drugs, McKesson has developed the Lifestyle Drug Monitoring Program (LDMP). This program began on May 1, 2007 and focuses on four drugs: Oxycodone, Hydrocodone, Phentermine and Alprazolam. Shipment and monitoring of these drugs will be measured by "dose units" rather than "sell units" with 8,000 dose units as the threshold for excessive quantities. The LDMP will also monitor customers exceeding the threshold, reduce orders if necessary and provide documentation and reporting to the DEA.

To help us better comply with DEA, please complete the following form and return it to me by Date. If you have any questions, please don't hesitate to contact me at XXX-XXX-XXXX.

Thank you,

VPSS
Vice President Strategic Solutions
McKesson Corporation

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000023

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001345
MCKMDL00355549

DEF-WV-01527.00023



DECLARATION OF CONTROLLED SUBSTANCES PURCHASES

1. _____ [company name] (hereinafter "Company")
located at _____ [address, city and state] maintains
retail pharmacies nationwide that are registered with the Drug Enforcement Administration to
distribute controlled substances ("Pharmacies").
2. Company declares and attests that its Pharmacies fully comply with all federal and state laws and
regulations on the dispensing of controlled substances including but not limited to dispensing to
patients only pursuant to a legitimate prescription issued in the course of an established doctor-
patient relationship (e.g., pursuant to a physical examination) and only for a legitimate medical
purpose.
3. Company will not knowingly dispense controlled substances for prescriptions that have been
received by its Pharmacies via the Internet, mail-order, or other non-walk-in customer where it has
reason to believe that the prescription was issued without a legitimate medical purpose.
4. Company states that the requirements of its Pharmacies for purchases of Lifestyle Drugs (e.g.,
hydrocodone, phentermine, alprazolam, oxycodone) from McKesson are necessary for the following
reasons: *[please describe the reason for purchasing these drugs in the quantities requested
including information about the prescriber and the general purposes for which the drugs are being
prescribed.]*

5. Company certifies that it has made sufficient inquiry to be able to make this declaration truthfully,
accurately and without material omissions. Company affirms by signing this declaration that all of
the above information is true and correct to the best of its knowledge and belief.

Signature

Printed Name of Signer

Title

Date

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000024

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001346
MCKMDL00355550

DEF-WV-01527.00024

Pharmacy Questionnaire

Pharmacy Name: _____

Customer Number: _____

DEA Number: _____

Date: _____

McKesson Sales Associate: _____

Customer Representative: _____

Survey Questions

1. Have you physically inspected the pharmacy?
 - a. Is it located in a normal retail environment?
 - b. If not in a normal retail environment, describe the location (industrial park, warehouse area, non-medical office building, etc.)
2. Does the pharmacy accept walk-in customers?
 - a. Estimated daily traffic?
3. Does the pharmacy purchase a wide range of drug products from distributors?
4. Has the pharmacy requested to pick up orders rather than have them delivered to the pharmacy (will calls)?
5. If the pharmacy has a web site or is related to a web site:

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000025

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001347
MCKMDL00355551

DEF-WV-01527.00025

Pharmacy Questionnaire

- a. Are reasonable retail prices listed on the website?
 - b. Is there a patient medical history questionnaire on the website?
 - c. Does the prescribing doctor perform a physical exam of each patient?
 - d. Does the website accept third party payment (insurance) for the internet prescriptions?
 - e. Does the website offer to sell drugs without a prescription?
6. Is the pharmacy VIPPS (Verified Internet Pharmacy Practice Sites) certified? (check the National Board of Pharmacy website)
- a. If not, why not?
 - b. What certification do they have, and how does it compare to VIPPS?
7. Who pays the distributor for the drugs, the pharmacy or a third party?
8. How many prescriptions for the following products does the pharmacy fill on a daily basis?
- a. Hydrocodone:
 - b. Alprazolam:
 - c. Phentermine:
 - d. Oxycodone:

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000026

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001348
MCKMDL00355552

DEF-WV-01527.00026

Pharmacy Questionnaire

9. Estimate the number or percentage of prescriptions received by category, that are:
- walk-ins
 - faxed prescriptions
 - phoned-in prescriptions
 - mailed prescriptions

Also, how are these prescriptions received, that is, faxed from LTC facility, faxed from doctor's office, faxed/mailed by patient?

10. Are prescriptions received from many states or primarily from Florida?
- How many states do they ship to?
 - In how many states is the customer licensed?

11. How many doctors do they prescribe for?

- Are they concentrated in a specific area?
- Are the doctors close to where the customers are?

12. Does the pharmacy have any agreements with Internet companies and does the pharmacy receive prescriptions from these providers?

13. What steps are taken to ensure the prescriptions have been issued by a practitioner pursuant to a valid doctor-patient relationship (e.g., has the doctor examined the patient?

- Are calls made to practitioners to verify the scripts)?

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000027

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001349
MCKMDL00355553

DEF-WV-01527.00027

**DECLARATION OF
CONTROLLED SUBSTANCES PURCHASES**

1. _____ [pharmacy name] (hereinafter "Pharmacy") located at
_____ [address, city and state] is registered
with the Drug Enforcement Administration (DEA), _____ [DEA
registration #].

2. Pharmacy declares and attests that it fully complies with all federal and state laws and regulations on the dispensing of controlled substances including but not limited to dispensing to patients only pursuant to a legitimate prescription issued in the course of an established doctor-patient relationship (e.g., pursuant to a physical examination) and only for a legitimate medical purpose.

3. Pharmacy will not knowingly dispense controlled substances for prescriptions that have been received via the internet, mail-order, or other non-walk-in customer where it has reason to believe that the prescription was issued without a legitimate medical purpose.

4. Pharmacy states that its requirements for purchases of Lifestyle Drugs (e.g., hydrocodone, phentermine, alprazolam, oxycodone) from McKesson are necessary for the following reasons: *[please describe the reason for purchasing these drugs in the quantities requested including information about the prescriber and the general purposes for which the drugs are being prescribed.]*

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000028

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001350
MCKMDL00355554

DEF-WV-01527.00028

5. Pharmacy certifies that it has made sufficient inquiry to be able to make this declaration truthfully, accurately and without material omissions. Pharmacy affirms by signing this declaration that the above is true and correct to the best of its knowledge and belief.

Signature

Printed Name of Signer

Title

Date

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000029

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001351
MCKMDL00355555

DEF-WV-01527.00029

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
BA9422469	506688	8185	PM0000771	8,000	AETNA RX HOME DEL-EDI ORD	ALPRAZOLAM	256	228	148,040
BA9422469	506688	8185	PM0000771	8,000	AETNA RX HOME DEL-EDI ORD	HYDROCODONE	381	355	120,877
BA9422469	506688	8185	PM0000771	8,000	AETNA RX HOME DEL-EDI ORD	OXYCODONE	420	383	38,300
AA7378905	391593	8185	PM0000771	8,000	ALBERTSONS #4301 RX	OXYCODONE	87	87	8,700
AA7378978	491807	8185	PM0000771	8,000	ALBERTSONS #4302 RX	OXYCODONE	86	86	13,400
AA7379008	850297	8185	PM0000771	8,000	ALBERTSONS #4314 RX	OXYCODONE	82	82	8,117
AA836918	148534	8185	PM0000771	8,000	ALBERTSONS #4327 RX	OXYCODONE	88	88	8,701
AA8391409	149642	8185	PM0000771	8,000	ALBERTSONS #4328 RX	OXYCODONE	187	183	12,738
AA8918948	151712	8185	PM0000771	8,000	ALBERTSONS #4345 RX	OXYCODONE	81	81	8,100
AA1455852	336603	8185	PM0000771	8,000	ALBERTSONS #4353 RX	OXYCODONE	85	87	8,700
BA1973930	244754	8185	PM0000771	8,000	ALBERTSONS #4429 RX	OXYCODONE	84	83	8,300
BA7169470	855317	8185	PM0000771	8,000	ALBERTSONS #4464 RX	OXYCODONE	88	88	8,402
BA8158221	469528	8185	PM0000771	8,000	ALBERTSONS #4458 RX	OXYCODONE	87	87	9,500
BA7268003	349715	8185	PM0000771	8,000	ALBERTSONS #4474 RX	OXYCODONE	107	105	8,312
BA7768148	727158	8185	PM0000771	8,000	ALBERTSONS #4484 RX	OXYCODONE	85	83	8,217
B38292683	308558	8185	PM0000771	8,000	AMERIDRUG-ST PETE USA	HYDROCODONE	21	21	8,816
AA3084214	849943	8185	PM0000771	8,000	AROTHEARY AT MEMORIAL	OXYCODONE	124	122	12,500
BO8158914	710190	8185	PM0000771	8,000	ARS LONGWOOD	OXYCODONE	413	407	38,897
BO1870548	471509	8185	PM0000771	8,000	ARNOLD PALMER HOSPITAL	OXYCODONE	120	120	12,000
BA5362847	089201	8185	PM0000771	8,000	ARTHUR'S ORIGINAL PHCY	OXYCODONE	173	171	17,741
BA5507843	417842	8185	PM0000771	8,000	A & W DRUG, INC	ALPRAZOLAM	23	28	8,160
BA5507843	417842	8185	PM0000771	8,000	A & W DRUG, INC	HYDROCODONE	85	76	20,216
BB4772225	087338	8185	PM0000771	8,000	BAPTIST MEDICAL ARTS HM	OXYCODONE	356	358	35,445
BB085558	848483	8185	PM0000771	8,000	BAYA PHCY EAST	HYDROCODONE	32	30	8,748
B38100327	735671	8185	PM0000771	8,000	BAYA PHCY JASPER	HYDROCODONE	56	32	8,898
AG2682092	889820	8185	PM0000771	8,000	BAYA PHCY WEST	HYDROCODONE	62	47	17,584
AG2682092	889820	8185	PM0000771	8,000	BAYA PHCY WEST	OXYCODONE	203	203	20,300
BB6085218	080784	8185	PM0000771	8,000	BAY PHARMACY	OXYCODONE	281	232	55,307
AD1187588	887729	8185	PM0000771	8,000	BERRY HILL PHARMACY	HYDROCODONE	27	24	8,832
AD8088214	885877	8185	PM0000771	8,000	BEST DRUGS-TRENTON	ALPRAZOLAM	9	9	8,100
AD8088214	885877	8185	PM0000771	8,000	BEST DRUGS-TRENTON	HYDROCODONE	36	31	14,880
AD8088214	885877	8185	PM0000771	8,000	BEST DRUGS-TRENTON	OXYCODONE	128	128	16,200
AG5004407	878885	8185	PM0000771	8,000	BILLS PRESCRIPTION	ALPRAZOLAM	49	40	25,780
AG5004407	878885	8185	PM0000771	8,000	BILLS PRESCRIPTION	HYDROCODONE	23	21	8,332
AG5004407	878885	8185	PM0000771	8,000	BILLS PRESCRIPTION	OXYCODONE	435	423	48,895
BB7487414	278986	8185	PM0000771	8,000	BOGA PHARMACY AND HHC #2	OXYCODONE	183	81	8,508
B32534878	888248	8185	PM0000771	8,000	BOGA PHARMACY & HHC	OXYCODONE	107	107	11,900
BB4810835	178015	8185	PM0000771	8,000	BUDGET DRUGS #4	ALPRAZOLAM	22	22	12,520
BB4810835	178015	8185	PM0000771	8,000	BUDGET DRUGS #4	HYDROCODONE	48	48	15,128
BB4810835	178015	8185	PM0000771	8,000	BUDGET DRUGS #4	OXYCODONE	165	184	20,400
BB5701108	818885	8185	PM0000771	8,000	BURKLOW PHARMACY	ALPRAZOLAM	21	21	11,080
BB5701108	818885	8185	PM0000771	8,000	BURKLOW PHARMACY	HYDROCODONE	88	85	18,568
AC5673787	824850	8185	PM0000771	8,000	CANTONMENT PHARMACY INC	OXYCODONE	139	139	14,700
BC8810354	897200	8185	PM0000771	8,000	CAREMARK (MAR) FDC NEW	ALPRAZOLAM	88	88	28,480
BC8810354	897200	8185	PM0000771	8,000	CAREMARK (MAR) FDC NEW	HYDROCODONE	118	102	17,548
BC8810354	897200	8185	PM0000771	8,000	CAREMARK (MAR) FDC NEW	OXYCODONE	598	587	81,552
BC8999949	837818	8185	PM0000771	8,000	CENTER CITY PHARMACY HM	OXYCODONE	174	172	18,560
BC7577375	221650	8185	PM0000771	8,000	CENTURY PHARMACY, LLO	HYDROCODONE	34	32	22,712
AC0168987	389213	8185	PM0000771	8,000	CHEEK PHCY/RX DEPT ACC HM	HYDROCODONE	57	42	13,948
AC0168987	389213	8185	PM0000771	8,000	CHEEK PHCY/RX DEPT ACC HM	OXYCODONE	105	102	12,800
BC1704493	487184	8185	PM0000771	8,000	CITY DRUGS OF CHIPLEY	HYDROCODONE	93	30	11,495
BC5950387	907022	8185	PM0000771	8,000	COMPSCRIPT-BOGA	OXYCODONE	58	58	14,800
BC8072056	354888	8185	PM0000771	8,000	COSTCO #093 PHCY	OXYCODONE	146	148	14,800
BC5040378	354870	8185	PM0000771	8,000	COSTCO #183 PHCY	ALPRAZOLAM	70	70	10,600
BC5040378	354870	8185	PM0000771	8,000	COSTCO #183 PHCY	HYDROCODONE	85	88	17,518
BC5040378	354870	8185	PM0000771	8,000	COSTCO #183 PHCY	OXYCODONE	118	111	12,708
BC8450720	860352	8185	PM0000771	8,000	COSTCO #184 PHCY	OXYCODONE	78	78	10,000
BC8586888	950873	8185	PM0000771	8,000	COSTCO #185 PHCY	OXYCODONE	85	88	9,000
BC8275818	037488	8185	PM0000771	8,000	COSTCO #338 PHCY	HYDROCODONE	41	41	8,818
BC8506870	950394	8185	PM0000771	8,000	COSTCO #351 PHCY	HYDROCODONE	35	33	8,418
BC8586878	950915	8185	PM0000771	8,000	COSTCO #354 PHCY	OXYCODONE	114	111	11,100

Confidentiality Notice: This document is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

Page 59 of 115

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000030

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001352
MCKMDL00355556

DEF-WV-01527.00030

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
BC7039690	757857	8195	PM0000771	8,000	COSTCO #357 PHCY	ALPRAZOLAM	600	558	58,400
BC7039690	757857	8195	PM0000771	8,000	COSTCO #357 PHCY	HYDROCODONE	544	481	48,732
BC7039690	757857	8195	PM0000771	8,000	COSTCO #357 PHCY	OXYCODONE	250	250	25,000
BC7040368	050188	8195	PM0000771	8,000	COSTCO #358 PHCY	ALPRAZOLAM	51	81	13,020
BC7040368	050188	8195	PM0000771	8,000	COSTCO #358 PHCY	HYDROCODONE	95	85	13,188
BC7040368	050188	8195	PM0000771	8,000	COSTCO #358 PHCY	OXYCODONE	104	89	10,500
BD3442287	405847	8195	PM0000771	8,000	DENNIS' PHARMACY	ALPRAZOLAM	38	27	19,500
BD3442287	405847	8195	PM0000771	8,000	DENNIS' PHARMACY	HYDROCODONE	104	58	26,800
BD3442287	405847	8195	PM0000771	8,000	DENNIS' PHARMACY	OXYCODONE	134	134	21,600
BD2258990	035211	8195	PM0000771	8,000	DEPT OF VA OUTPATIENT	ALPRAZOLAM	18	18	18,500
BD2258990	035211	8195	PM0000771	8,000	DEPT OF VA OUTPATIENT	OXYCODONE	228	228	22,800
AD0212058	772378	8195	PM0000771	8,000	DOCTORS PHARMACY	ALPRAZOLAM	87	87	20,000
BE1971743	888832	8195	PM0000771	8,000	EDISON PRESCRIPTION HML	ALPRAZOLAM	12	12	16,500
BE8973720	671818	8195	PM0000771	8,000	EXPRESS PHCY SVCS OF FL	OXYCODONE	354	354	54,212
BF058048	575242	8195	PM0000771	8,000	FAMILYMEDS PHCY 728	HYDROCODONE	53	435	15,018
BF7454854	544417	8195	PM0000771	8,000	FLAGLER COMMUNITY PHCY INC	ALPRAZOLAM	35	35	9,200
BF7454854	544417	8195	PM0000771	8,000	FLAGLER COMMUNITY PHCY INC	HYDROCODONE	1149	72	24,876
BF7454854	544417	8195	PM0000771	8,000	FLAGLER COMMUNITY PHCY INC	OXYCODONE	128	128	14,800
BF0240820	551822	8195	PM0000771	8,000	FLETCHER MEDICAL CENTER	OXYCODONE	178	177	12,452
BR9611408	818630	8195	PM0000771	8,000	FRIMADE COMM PHCY HM	HYDROCODONE	145	141	13,896
BJ3676458	049098	8195	PM0000771	8,000	GARDEN DRUGS	ALPRAZOLAM	148	142	67,000
BJ3676458	049098	8195	PM0000771	8,000	GARDEN DRUGS	HYDROCODONE	58	68	18,400
BJ3676458	049098	8195	PM0000771	8,000	GARDEN DRUGS	OXYCODONE	4,714	4,554	74,288
BG9502089	288870	8195	PM0000771	8,000	GARDENS DRUGS INC	OXYCODONE	133	133	8,746
BG2223294	074880	8195	PM0000771	8,000	GOLDEN PHCY INC GRP SHM	HYDROCODONE	82	74	11,780
BG8271900	873159	8195	PM0000771	8,000	GULF SHORE PHARMACY INC	OXYCODONE	75	74	8,447
BH4727270	380248	8195	PM0000771	8,000	HEARTLAND HLTH SVC	OXYCODONE	78	78	21,328
AH0188583	773702	8195	PM0000771	8,000	HEDGES PRESCRIPTION SH HM	ALPRAZOLAM	44	38	8,000
AH0188583	773702	8195	PM0000771	8,000	HEDGES PRESCRIPTION SH HM	HYDROCODONE	44	27	11,018
AH0188583	773702	8195	PM0000771	8,000	HEDGES PRESCRIPTION SH HM	OXYCODONE	205	201	21,108
AH0184834	689030	8195	PM0000771	8,000	HOLY CROSS HOSPITAL	OXYCODONE	134	134	6,500
BF3800059	881899	8195	PM0000771	8,000	HOSPICE OF THE FLORIDA	OXYCODONE	181	181	8,983
BF8408709	807713	8195	PM0000771	8,000	HPH PHARMACY & MED EQUIP	HYDROCODONE	73	73	6,004
EH6408709	807713	8195	PM0000771	8,000	HPH PHARMACY & MED EQUIP	OXYCODONE	977	977	15,920
BH452102	048486	8195	PM0000771	8,000	HUBER	OXYCODONE	89	89	9,102
BH1076787	820048	8195	PM0000771	8,000	HUMANA PHARM 47814	ALPRAZOLAM	38	38	18,800
BJ0419839	880378	8195	PM0000771	8,000	JAMES A HALEY/VA MED C/P	OXYCODONE	2,128	2,128	12,280
BJ732402	043024	8195	PM0000771	8,000	JERRY'S DRUG	OXYCODONE	126	126	12,636
BK7688455	844284	8195	PM0000771	8,000	KINGS PHARMACY	OXYCODONE	121	121	12,708
BF8052285	433588	8195	PM0000771	8,000	KINGS PHCY BOYNTON	OXYCODONE	68	68	12,101
BL6219314	074022	8195	PM0000771	8,000	LEAPATH HOSPICE	ALPRAZOLAM	37	37	18,018
BL6219314	074022	8195	PM0000771	8,000	LEAPATH HOSPICE	OXYCODONE	600	600	47,765
AL8903745	093005	8195	PM0000771	8,000	LITTLE DRUG CO INC HM	HYDROCODONE	25	25	6,332
AL0210188	049023	8195	PM0000771	8,000	LIVE & LET LIVE	OXYCODONE	117	117	18,100
BM8212855	770595	8195	PM0000771	8,000	MADISON STREET PHARMACY	ALPRAZOLAM	41	41	14,020
BM8212855	770595	8195	PM0000771	8,000	MADISON STREET PHARMACY	HYDROCODONE	141	100	27,372
BM8212855	770595	8195	PM0000771	8,000	MADISON STREET PHARMACY	OXYCODONE	240	239	27,997
BK8801843	135287	8195	PM0000771	8,000	MEDCAP PHARMACY	OXYCODONE	1,413	1,377	128,500
BO8838740	232007	8195	PM0000771	8,000	MEDISTAT PHARMACY	OXYCODONE	531	489	48,900
BO8838752	385328	8195	PM0000771	8,000	MEDISTAT PHCY SVCS	OXYCODONE	544	345	32,124
BM4834821	975154	8195	PM0000771	8,000	MEM HSP OF JACKSONVILLE	OXYCODONE	187	187	11,817
BD9551118	714286	8195	PM0000771	8,000	MILLER'S HEALTHMART PHCY	OXYCODONE	68	68	8,880
BD3311680	838316	8195	PM0000771	8,000	MMS/DE CESPEDES, RAUL	OXYCODONE	178	103	12,712
BL9581235	182244	8195	PM0000771	8,000	MMS/LAZZOPINA, MICHAEL	ALPRAZOLAM	23	22	9,000
BL9581235	182244	8195	PM0000771	8,000	MMS/LAZZOPINA, MICHAEL	OXYCODONE	158	158	15,600
AB8135849	889788	8195	PM0000771	8,000	MMS/NORMAN B BAMBERG	OXYCODONE	74	74	9,800
BE7782650	859782	8195	PM0000771	8,000	MMS/PAIN CARE 1ST ORLANDO	OXYCODONE	188	172	17,800
AK2888858	858793	8195	PM0000771	8,000	MMS/PAIN CARE ASSOC INC	OXYCODONE	306	180	18,000
BS9363691	858807	8195	PM0000771	8,000	MMS/PAIN MGMT CTR IN	OXYCODONE	231	174	14,636
AP8300684	858807	8195	PM0000771	8,000	MMS/PAIN MGMT CTR IN	OXYCODONE	424	390	29,908
AS9122045	180385	8195	PM0000771	8,000	MMS/SWARTZ, FREDRIC	OXYCODONE	155	135	13,500

Confidentiality Notice: This document is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

Page 100 of 115

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000031

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001353
MCKMDL00355557

DEF-WV-01527.00031

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
AW7215191	280325	8195	PM0000771	8,000	MMS/WILSON WILLIAMS MD PA	ALPRAZOLAM	32	20	10,000
AW7215191	280325	8195	PM0000771	8,000	MMS/WILSON WILLIAMS MD PA	HYDROCODONE	26	16	8,000
AW7215191	280325	8195	PM0000771	8,000	MMS/WILSON WILLIAMS MD PA	OXYCODONE	376	376	25,820
BN3353365	405373	8195	PM0000771	8,000	NAPIER PHARMACY INC	HYDROCODONE	83	42	18,712
BN3353365	888572	8195	PM0000771	8,000	NAPIER PHARMACY INC EDI	ALPRAZOLAM	25	25	11,660
BN3353365	888572	8195	PM0000771	8,000	NAPIER PHARMACY INC EDI	HYDROCODONE	87	44	18,432
BN3353365	888572	8195	PM0000771	8,000	NAPIER PHARMACY INC EDI	OXYCODONE	107	107	10,700
BN8161812	836083	8195	PM0000771	8,000	NORTH FLORIDA REG PHCY	OXYCODONE	121	121	12,100
FO0062690	239218	8195	PM0000771	8,000	ORH SCRIPTS	OXYCODONE	397	347	31,021
AO7450238	820815	8195	PM0000771	8,000	ORLANDO REGIONAL MED CTR	OXYCODONE	423	423	27,380
BO6891657	825054	8195	PM0000771	8,000	OSBORNE PHARM INC HM	ALPRAZOLAM	13	13	8,000
BO6891657	825054	8195	PM0000771	8,000	OSBORNE PHARM INC HM	OXYCODONE	418	404	41,224
BO6163047	082438	8195	PM0000771	8,000	OSCEOLA PHARMACY - PPSC	ALPRAZOLAM	9	9	8,000
AO6153047	082438	8195	PM0000771	8,000	OSCEOLA PHARMACY - PPSC	HYDROCODONE	39	39	8,398
AO6163047	082438	8195	PM0000771	8,000	OSCEOLA PHARMACY - PPSC	OXYCODONE	89	89	10,700
AP7120594	049007	8195	PM0000771	8,000	PARK DRIVE HM	OXYCODONE	317	317	32,270
BP8917088	887377	8195	PM0000771	8,000	PASCO PHARMACY	OXYCODONE	179	175	17,900
BP8168842	935814	8195	PM0000771	8,000	PAVILION PLAZA LANE HM	HYDROCODONE	31	29	8,480
BP0244979	552935	8195	PM0000771	8,000	PAVILION PLAZA PHCY PPBHM	ALPRAZOLAM	20	20	10,680
BP0244979	552935	8195	PM0000771	8,000	PAVILION PLAZA PHCY PPBHM	HYDROCODONE	75	75	18,412
BP0244979	552935	8195	PM0000771	8,000	PAVILION PLAZA PHCY PPBHM	OXYCODONE	163	163	16,100
BP8168842	961504	8195	PM0000771	8,000	PAVILION PLAZA REG PHCY HM	HYDROCODONE	31	28	10,380
AP0200612	550974	8195	PM0000771	8,000	PAXON PRESC CNTR EDI	ALPRAZOLAM	39	39	18,800
AP0200612	550974	8195	PM0000771	8,000	PAXON PRESC CNTR EDI	HYDROCODONE	105	82	37,400
BM4837231	768348	8195	PM0000771	8,000	PHARMACY SERVICE GROUP	HYDROCODONE	41	41	10,072
BM4837231	768348	8195	PM0000771	8,000	PHARMACY SERVICE GROUP	OXYCODONE	231	207	12,344
BM5609188	170883	8195	PM0000771	8,000	PILL BOX III HM	OXYCODONE	110	110	8,538
AP3078568	251831	8195	PM0000771	8,000	PILL BOX PHARMACY	OXYCODONE	104	134	14,604
BM3100885	254848	8195	PM0000771	8,000	PILL BOX PHARMACY II HM	OXYCODONE	182	182	17,148
BD4394833	228378	8195	PM0000771	8,000	PLAZA DENNIS PHCY HM	OXYCODONE	93	93	10,900
BL3052781	084831	8195	PM0000771	8,000	POST HASTE PHARMACY	OXYCODONE	248	238	21,228
BP8898528	880226	8195	PM0000771	8,000	PRESCRIBIT RX LLC 45530	ALPRAZOLAM	28	28	10,800
BP8898528	880226	8195	PM0000771	8,000	PRESCRIBIT RX LLC 45537	ALPRAZOLAM	16	16	8,000
BP8898528	880226	8195	PM0000771	8,000	PRESCRIBIT RX LLC 45538	ALPRAZOLAM	25	25	14,500
BP8898528	880226	8195	PM0000771	8,000	PRESCRIBIT RX LLC 45540	ALPRAZOLAM	48	48	20,800
AP8898528	880226	8195	PM0000771	8,000	PRESCRIPTION DRUG FOUND	OXYCODONE	128	127	13,805
AP2125189	230607	8195	PM0000771	8,000	PRESCRIPTION UNLIMITED	HYDROCODONE	63	62	13,484
AP2125189	230607	8195	PM0000771	8,000	PRESCRIPTION UNLIMITED	OXYCODONE	130	128	12,587
AP7008887	878838	8195	PM0000771	8,000	PRESTON REXALL PHARMACY	OXYCODONE	89	69	8,300
BP8483353	594140	8195	PM0000771	8,000	PUBLIX PHCY #0019	OXYCODONE	88	85	8,708
BP2976160	883183	8195	PM0000771	8,000	PUBLIX PHCY #0053	OXYCODONE	72	72	8,868
BP8383854	474138	8195	PM0000771	8,000	PUBLIX PHCY #0141	OXYCODONE	73	73	8,203
BP1685848	285803	8195	PM0000771	8,000	PUBLIX PHCY #0381	OXYCODONE	86	81	10,533
BP1823882	451219	8195	PM0000771	8,000	PUBLIX PHCY #0371	OXYCODONE	78	72	8,800
BP1797048	728066	8195	PM0000771	8,000	PUBLIX PHCY #0373	OXYCODONE	79	73	8,904
BP2817320	203478	8195	PM0000771	8,000	PUBLIX PHCY #0411	OXYCODONE	86	88	8,400
BP3470058	378868	8195	PM0000771	8,000	PUBLIX PHCY #0435	OXYCODONE	85	85	10,553
BP6019382	688339	8195	PM0000771	8,000	PUBLIX PHCY #0445	OXYCODONE	92	82	10,200
BP3821685	384872	8195	PM0000771	8,000	PUBLIX PHCY #0457	OXYCODONE	231	196	24,000
BP4348341	238059	8195	PM0000771	8,000	PUBLIX PHCY #0523	OXYCODONE	82	82	10,200
BP4477142	884438	8195	PM0000771	8,000	PUBLIX PHCY #0527	OXYCODONE	108	78	8,817
BP5821798	813728	8195	PM0000771	8,000	PUBLIX PHCY #0820	OXYCODONE	118	110	13,804
BP5883887	212281	8195	PM0000771	8,000	PUBLIX PHCY #0631	OXYCODONE	82	58	8,000
BP7703792	487878	8195	PM0000771	8,000	PUBLIX PHCY #0767	OXYCODONE	74	74	8,008
BP7944875	809516	8195	PM0000771	8,000	PUBLIX PHCY #0780	OXYCODONE	80	78	8,200
BP7429334	371931	8195	PM0000771	8,000	PUBLIX PHCY #0782	OXYCODONE	72	65	8,100
BP7587009	522188	8195	PM0000771	8,000	PUBLIX PHCY #0813	OXYCODONE	110	107	14,700
BP8272016	880381	8195	PM0000771	8,000	PUBLIX PHCY #0851	OXYCODONE	91	89	11,217
BP7860190	550930	8195	PM0000771	8,000	PUBLIX PHCY #0854	OXYCODONE	77	68	8,200
BP9541257	583188	8195	PM0000771	8,000	PUBLIX PHCY #1007	OXYCODONE	67	62	8,200
BP9535519	583178	8195	PM0000771	8,000	PUBLIX PHCY #1037	OXYCODONE	90	85	8,800

Confidentiality Notice: This document is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

Page 101 of 115

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000032

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001354
MCKMDL00355558

DEF-WV-01527.00032

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
BR4848208	049981	8185	PM0000771	8,000	RELIABLE SUPER DRUGS	HYDROCODONE	107	98	18,500
BR4848208	049981	8185	PM0000771	8,000	RELIABLE SUPER DRUGS	OXYCODONE	135	135	23,900
AS3148500	889825	8185	PM0000771	8,000	ROMANO'S PHARMACY	OXYCODONE	148	148	14,418
BR9508954	831783	8185	PM0000771	8,000	RXPRT #1 LLC	ALPRAZOLAM	50	45	18,080
BR9508954	831783	8185	PM0000771	8,000	RXPRT #1 LLC	HYDROCODONE	54	32	14,000
FR0003981	814725	8185	PM0000771	8,000	RXPRT #3 LLC	HYDROCODONE	142	96	12,400
FR0003981	814725	8185	PM0000771	8,000	RXPRT #3 LLC	OXYCODONE	120	120	12,000
AB0177354	157648	8185	PM0000771	8,000	SACHED HEART HOSP O/P PHS	HYDROCODONE	36	35	9,080
BP3880084	406355	8185	PM0000771	8,000	SAN MARCO PAVILION PHCY/IM	HYDROCODONE	24	23	10,400
BS8488045	788744	8185	PM0000771	8,000	SANTA ROSE PHARMACY EDI	ALPRAZOLAM	111	111	8,080
BS8488045	788744	8185	PM0000771	8,000	SANTA ROSE PHARMACY EDI	HYDROCODONE	83	47	18,448
BC8884207	782914	8185	PM0000771	8,000	SAVA LOT PHCY/CLAUDEHILL	OXYCODONE	148	148	14,280
BG9884184	782853	8185	PM0000771	8,000	SAVA LOT PHCY/MARGATE	OXYCODONE	88	88	11,405
BD9071273	887811	8185	PM0000771	8,000	SAVE A LOT PHCY	ALPRAZOLAM	18	16	9,880
BD9071273	887811	8185	PM0000771	8,000	SAVE A LOT PHCY	OXYCODONE	48	48	8,400
AS8841428	088206	8185	PM0000771	8,000	SCHAEFER DRUG INC 2	ALPRAZOLAM	75	71	13,800
AS8841428	088206	8185	PM0000771	8,000	SCHAEFER DRUG INC 2	OXYCODONE	118	118	40,841
BA5180373	822158	8185	PM0000771	8,000	SE FAMILY HLT CTR PHS EDI	HYDROCODONE	115	115	11,418
BS8348725	893157	8185	PM0000771	8,000	SENTRY DRUGS EAST HM	HYDROCODONE	48	48	9,328
BS8348725	893157	8185	PM0000771	8,000	SENTRY DRUGS EAST HM	OXYCODONE	570	570	69,404
BS7084697	175950	8185	PM0000771	8,000	SETON PHCY/BARRS	HYDROCODONE	28	23	26,312
FL0184938	776785	8185	PM0000771	8,000	SEVEN HILLS PHARMACY HM	ALPRAZOLAM	12	11	8,000
AD8470828	068882	8185	PM0000771	8,000	SHANDS HOSP INPATN IDG 18	OXYCODONE	185	185	9,813
BS8523282	241880	8185	PM0000771	8,000	SHANDS JACKSONVILLE MCAP	OXYCODONE	279	277	23,820
BS8523282	584787	8185	PM0000771	8,000	SHANDS JAX MED CTR/OR PHS	ALPRAZOLAM	188	168	16,900
BS8523282	584787	8185	PM0000771	8,000	SHANDS JAX MED CTR/OR PHS	HYDROCODONE	1683	801	79,596
BS8523282	584787	8185	PM0000771	8,000	SHANDS JAX MED CTR/OR PHS	OXYCODONE	387	387	39,817
BS8566668	128342	8185	PM0000771	8,000	SHANDS JAX PLAZA PHCY	HYDROCODONE	108	102	10,118
BS8078102	121883	8185	PM0000771	8,000	SHANDS MEDICAL PLAZA PHS	OXYCODONE	108	103	14,059
AD8470828	088148	8185	PM0000771	8,000	SHANDS OUTPATIENT PHCY/PHS	OXYCODONE	120	120	10,887
BS6599388	851004	8185	PM0000771	8,000	SNEADS PHARMACY	HYDROCODONE	25	23	9,932
BP4801183	544130	8185	PM0000771	8,000	STEGER DRUG CO/PPSCHM	HYDROCODONE	168	43	14,860
BP4801183	544130	8185	PM0000771	8,000	STEGER DRUG CO/PPSCHM	OXYCODONE	143	143	14,300
BS8780834	011887	8185	PM0000771	8,000	ST JOHNS PHARMACY	ALPRAZOLAM	28	28	9,380
BS8780834	011887	8185	PM0000771	8,000	ST JOHNS PHARMACY	HYDROCODONE	56	62	20,716
BS8780834	011887	8185	PM0000771	8,000	ST JOHNS PHARMACY	OXYCODONE	178	118	12,600
BT7347328	055503	8185	PM0000771	8,000	ST MARYS MEDICAL CTR 0847	OXYCODONE	118	118	16,880
AS5131228	528728	8185	PM0000771	8,000	ST VINCENTS MED CTR/JAX	OXYCODONE	107	107	9,500
BS5104928	644254	8185	PM0000771	8,000	SUN PHARMACY	OXYCODONE	118	101	28,947
BA8108320	248331	8185	PM0000771	8,000	SUNRISE DISCOUNT PHARMACY	ALPRAZOLAM	44	43	18,500
BA8108320	248331	8185	PM0000771	8,000	SUNRISE DISCOUNT PHARMACY	OXYCODONE	1632	582	62,986
BS8158245	513324	8185	PM0000771	8,000	SUNSHINE PHARMACY	OXYCODONE	207	188	21,111
BS9884487	191547	8185	PM0000771	8,000	SUNSHINE PHCY/AT DAVIS	OXYCODONE	65	57	18,340
BS7218565	330257	8185	PM0000771	8,000	SUNSHINE SOLUTIONS PHCY	OXYCODONE	81	81	10,387
BS5744845	645274	8185	PM0000771	8,000	SUNSHINE WELLNESS CTR	HYDROCODONE	47	47	10,912
BS5744845	645274	8185	PM0000771	8,000	SUNSHINE WELLNESS CTR	OXYCODONE	28	125	15,108
BF8851882	848484	8185	PM0000771	8,000	TAMPA GENERAL HOSPITAL	OXYCODONE	383	382	27,580
AC4530920	187820	8185	PM0000771	8,000	TARARA PHARMACY INC	ALPRAZOLAM	89	88	149,000
BT7880851	221385	8185	PM0000771	8,000	TARGET 0845 PHCY	HYDROCODONE	85	88	17,748
BT7880851	221385	8185	PM0000771	8,000	TARGET 0845 PHCY	OXYCODONE	88	88	18,600
BT2707529	805105	8185	PM0000771	8,000	TARGET 0851 PHCY	ALPRAZOLAM	18	18	16,000
BT2707529	805105	8185	PM0000771	8,000	TARGET 0851 PHCY	HYDROCODONE	74	61	14,418
BT2707492	805139	8185	PM0000771	8,000	TARGET 0854 PHCY	ALPRAZOLAM	35	35	18,540
BT2707492	805139	8185	PM0000771	8,000	TARGET 0854 PHCY	HYDROCODONE	103	84	19,032
BT3052228	805154	8185	PM0000771	8,000	TARGET 0888 PHCY	HYDROCODONE	39	39	8,724
BT3208198	805188	8185	PM0000771	8,000	TARGET 0889 PHCY	HYDROCODONE	68	54	10,488
BT3208198	805188	8185	PM0000771	8,000	TARGET 0889 PHCY	OXYCODONE	83	83	8,300
BT3398878	159808	8185	PM0000771	8,000	TARGET 0789 PHCY	HYDROCODONE	136	121	15,384
BT3398878	159808	8185	PM0000771	8,000	TARGET 0789 PHCY	OXYCODONE	241	241	24,017
BT3191397	804987	8185	PM0000771	8,000	TARGET 0811 PHCY	ALPRAZOLAM	37	37	9,280
BT3191397	804987	8185	PM0000771	8,000	TARGET 0811 PHCY	HYDROCODONE	68	65	16,744

Confidentiality Notice: This document is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

Page 102 of 115

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000033

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001355
MCKMDL00355559

DEF-WV-01527.00033

Cust DEA #	Acct #	DC	DC DEA #	Dosage Threshold	Account Name	Drug	Order Qty	Net Qty	Net Dosages
BT3317824	605022	8195	PM0000771	8,000	TARGET 0817 PHCY	ALPRAZOLAM	28	25	11,180
BT3317824	605022	8195	PM0000771	8,000	TARGET 0817 PHCY	HYDROCODONE	110	75	27,228
BT3317824	605022	8195	PM0000771	8,000	TARGET 0817 PHCY	OXYCODONE	108	108	10,402
BT3771208	605089	8195	PM0000771	8,000	TARGET 0874 PHCY	HYDROCODONE	40	33	9,048
BT4158768	490219	8195	PM0000771	8,000	TARGET 0910 PHCY	HYDROCODONE	85	84	10,716
BT4158768	490219	8195	PM0000771	8,000	TARGET 0910 PHCY	OXYCODONE	85	86	8,600
BT4817300	812402	8195	PM0000771	8,000	TARGET 1023 PHCY	ALPRAZOLAM	29	29	8,900
BT4817300	812402	8195	PM0000771	8,000	TARGET 1023 PHCY	HYDROCODONE	58	52	12,884
BT4817300	812402	8195	PM0000771	8,000	TARGET 1023 PHCY	OXYCODONE	150	150	15,404
BT5043778	850782	8195	PM0000771	8,000	TARGET 1083 PHCY	HYDROCODONE	97	55	9,892
BT5043778	850782	8195	PM0000771	8,000	TARGET 1083 PHCY	OXYCODONE	70	70	8,402
BT7825819	881892	8195	PM0000771	8,000	TARGET 1254 PHCY	HYDROCODONE	57	51	8,598
BT8393411	011340	8195	PM0000771	8,000	TARGET 1300 PHCY	ALPRAZOLAM	12	12	8,080
BT8393411	011340	8195	PM0000771	8,000	TARGET 1300 PHCY	HYDROCODONE	52	40	8,664
BT8641358	280781	8195	PM0000771	8,000	TARGET 1503 PHCY	HYDROCODONE	108	88	11,084
BT8507329	087818	8195	PM0000771	8,000	TARGET 1820 PHCY	ALPRAZOLAM	18	18	8,180
BT8507329	087818	8195	PM0000771	8,000	TARGET 1820 PHCY	HYDROCODONE	48	38	11,812
BT8507329	087818	8195	PM0000771	8,000	TARGET 1820 PHCY	OXYCODONE	88	86	8,800
BT8577411	822824	8195	PM0000771	8,000	TARGET 1853 PHCY	HYDROCODONE	47	31	8,532
BT8835123	881888	8195	PM0000771	8,000	TARGET 2155 PHCY	HYDROCODONE	45	37	11,912
BT9572783	884442	8195	PM0000771	8,000	TEQUESTA DRUGS	OXYCODONE	86	59	9,518
BP8433373	872533	8195	PM0000771	8,000	TBS MEDICINE SHOPPE/A	OXYCODONE	81	81	9,100
BP8350718	872484	8195	PM0000771	8,000	THE MEDICINE SHOPPE/D	HYDROCODONE	45	29	11,448
BU8503799	497868	8195	PM0000771	8,000	ULTIMA RX LLC	ALPRAZOLAM	44	44	20,000
BU9948948	841098	8195	PM0000771	8,000	UNIVERSITY PHARMACY INC	OXYCODONE	90	88	8,600
AV4277845	038871	8195	PM0000771	8,000	VA LAKE CITY OUTPATIENT	HYDROCODONE	480	480	48,000
AV4277845	038871	8195	PM0000771	8,000	VA LAKE CITY OUTPATIENT	OXYCODONE	955	955	94,887
BY0368787	825877	8195	PM0000771	8,000	VA MAYAGUEZ OUTPAT CLINIC	OXYCODONE	25	25	12,100
BY0484781	320878	8195	PM0000771	8,000	VA MC PHCY OP/PENSACOLA	HYDROCODONE	158	158	15,800
BY0484781	320878	8195	PM0000771	8,000	VA MC PHCY OP/PENSACOLA	OXYCODONE	108	108	10,800
AV4871372	847880	8195	PM0000771	8,000	VA MED CTR GAINESVILLE IP	HYDROCODONE	1,013	1,013	101,300
AV4871372	847880	8195	PM0000771	8,000	VA MED CTR GAINESVILLE IP	OXYCODONE	2,225	2,225	219,840
AV5307689	044708	8195	PM0000771	8,000	VA MED CTR VE CONTROLS	HYDROCODONE	772	772	69,472
AV5307689	044708	8195	PM0000771	8,000	VA MED CTR VE CONTROLS	OXYCODONE	720	201	20,100
BD2869395	131788	8195	PM0000771	8,000	VA MEDICAL CENTER	OXYCODONE	1,024	1,024	102,300
AV4346559	184782	8195	PM0000771	8,000	VA MEDICAL CENTER/WRAT	HYDROCODONE	268	268	28,500
AV863469	040817	8195	PM0000771	8,000	VA OUTPATIENT CLIN/ALMUS	HYDROCODONE	171	171	17,100
BY055704	882740	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	1,248	1,248	124,800
AV5214488	743845	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	HYDROCODONE	636	634	83,400
AV5214488	743845	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	182	182	19,200
BD4832618	627881	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	1,572	1,572	157,200
BY3485970	770541	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	HYDROCODONE	144	144	14,400
BY3485970	770541	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	174	174	17,400
BY4345315	653831	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	1,372	1,372	137,200
BY8322882	284288	8195	PM0000771	8,000	VA OUTPATIENT CLINIC	OXYCODONE	1,218	1,218	121,800
BW8785060	748571	8195	PM0000771	8,000	WELLINGTON DISC PHCY HM	HYDROCODONE	35	35	15,800
BW8785060	748571	8195	PM0000771	8,000	WELLINGTON DISC PHCY HM	OXYCODONE	289	286	30,501
BR9032551	812343	8195	PM0000771	8,000	WESTCHASE COMPOUNDING PHY	HYDROCODONE	24	19	8,616
AR0208228	678506	8195	PM0000771	8,000	XOA HABANA HOSPITAL PHCY	HYDROCODONE	40	38	10,348
AR0208228	678506	8195	PM0000771	8,000	XOA HABANA HOSPITAL PHCY	OXYCODONE	125	125	12,500
BY8654877	741098	8195	PM0000771	8,000	YAMATO DISCOUNT DRUGS HM	OXYCODONE	72	72	8,040
AA5030882	406991	8195	PM0000771	8,000	ZZATKINSON'S MART 5/30/07	OXYCODONE	150	150	12,655

Confidentiality Notice: This document is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

Page 103 of 115

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000034

Confidential - Subject to Protective Order
CONFIDENTIAL-SUBJECT TO MDL 2804 PROTECTIVE ORDER

MCK-WVAG-003-0001356
MCKMDL00355560

DEF-WV-01527.00034